


Geistlich Pharma AG
Business Unit Medical
Bahnhofstrasse 40
CH-6110 Wollhusen
Phone +41 41 492 56 25
Fax +41 41 492 67 14
taurosept@geistlich.ch
www.geistlich-medical.com

Roztwór do leczenia i zapobiegania zakażeniom odcewnikowym



- Antybakteryjny
- Przeciwgrzybiczy
- Zapobiega rozwojowi biofilmu



Literature

- Agharazi, M., J. Plamondon, et al. (2005). "Estimation of heparin leak into the systemic circulation after central venous catheter heparin lock." *Nephrol Dial Transplant* 20(6): 1238-40.
- Ailon et al. (2003). "Prophylaxis against Dialysis Catheter-Related Bacteremia with a Novel Antimicrobial Lock Solution." *Clinical Infectious Diseases* 2003; 36: 1539-44.
- Ash et al. (2000). "Concentrated Sodium Citrate (23%) for Catheter Lock." *Hemodialysis International*, Vol. 4, 2000.
- Baytes et al. (2004). "Prevention of dialysis catheter-related sepsis with a citrate-tauridine-containing lock solution." *Nephrol Dial Transplant* 2004; 19: 1546-1551.
- Bisseling, T. M., M. C. Willems, et al. (2010). "Tauridine lock is highly effective in preventing catheter-related bloodstream infections in patients on home parenteral nutrition: a heparin-controlled prospective trial." *Clin Nutr* 29(4): 464-8.
- Blenkham, J. I. (1988). "Sustained anti-adherence activity of tauridine (Taurolin) and oxxytholin (Noxyflex) solutions." *J Pharm Pharmacol* 40(7): 509-11.
- Critch C. J. (2005). "The effects of prolonged ethanol exposure on the mechanical properties of polyurethane and silicone catheters used for intravascular access." *Infect Control Hosp Epidemiol* 2005; 26.
- Dumichen, M. J., K. Seeger, et al. (2012). "Randomized controlled trial of tauridine citrate versus heparin as catheter lock solution in paediatric patients with haematological malignancies." *J Hosp Infect* 80(4): 304-9.
- Gong, L., H. E. Greenberg, et al. (2007). "The pharmacokinetics of tauridine metabolites in healthy volunteers." *J Clin Pharmacol* 47(6): 697-703.
- Geosensio G. A. (2013). "Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open-label." *Annals of Oncology* 24: 1897-1903.
- McCoy, P., D. F. McAfferly, et al. (1987). "Reduced adherence of microorganisms to mammalian epithelial cells following treatment with Taurolin, a novel antimicrobial agent." *J Appl Bacteriol* 62(4): 315-20.
- Gruzdinski et al. (2007). "Sodium citrate 4% locking solution for central venous dialysis catheters - an effective, more cost-efficient alternative to heparin." *Nephrol Dial Transplant* (2007) 22: 471-476.
- Landry DL et al. (2010). "Emergence of gentamicin-resistant bacteremia in hemodialysis patients receiving gentamicin lock catheter prophylaxis." *Clin J Am Soc Nephrol*. 2010 Oct; 5(10): 1799-804.
- Mermet LA, Alang N, (2014). "Adverse effects associated with ethanol catheter lock solutions: a systematic review." *J Antimicrob Chemother*. 2014 Oct; 69(10): 2611-9.
- Oliveira C. (2012). "Ethanol Lock to Prevent Catheter-Related Bloodstream Infections in Parenteral Nutrition: A Meta-Analysis." *Pediatrics* 2012; 129: 318.
- Olthof ED, et al., Absence of microbial adaptation to tauridine in patients on home parenteral nutrition who develop catheter related bloodstream infections and use tauridine locks. *Clinical Nutrition* (2012).
- Olthof et al. (2014). "Tauridine Lock Is Superior to Heparin Lock in the Prevention of Catheter-Related Bloodstream Infections and Occlusions." *PLoS ONE* 9(11): e112126.
- Onici (2013). "Optimal dosage and dwell time of ethanol lock therapy on catheters infected with *Candida* species." *Clinical Nutrition* 33 (2014) 360e362.
- Polaschegg and Shah "Overspill of Catheter Locking Solution: Safety and Efficacy Aspects." *ASAIO Journal* 2003; 49: 713-715.
- Power A.; (2009) "Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single-center randomized controlled trial." *Am J Kidney Dis* 2009; 53: 1034.
- Punt C. D., Boer W. E. 2008 "Cardiac arrest following injection of concentrated trisodium citrate." *Clinical Nephrology*, Vol. 59 - No. 4/2008.
- Reinmüller, Mutschler, Meyer: "Hemmung der Staphylokokken-Koagulase durch Taurolin." *Hämostaseologie* 1999; 19: 94-7.
- Schlicher et al. (2012). "Trisodium citrate induced protein precipitation in haemodialysis catheters might cause pulmonary embolism." *Nephrol Dial Transplant* (2012) 0: 1-5.
- Schlicher G, Schlägenhauf A, Schmedtitz D, Scharnagl H, Riblicsh W, et al. (2013). "Ethanol Causes Protein Precipitation - New Safety Issues for Catheter Locking Techniques". *PLoS ONE* 8(12): 75811.
- Shankis, R.K., N.P. Donegan, et al. (2005). "Heparin stimulates *Staphylococcus aureus* biofilm formation." *Infect Immun* 73(8): 4996-606.
- Simon A (2006). "Diagnosis and treatment of catheter-related infections in paediatric oncology: an update." *Clin Microbiol Infect* 2006; 12: 806-820.
- Tzoufopoulou, C., C. Thavain-Filippou, et al. (2000). "Activities of tauridine, in vitro, and in experimental enterococcal endocarditis." *Antimicrob Agents Chemother* 44(6): 1720-4.
- Traub, W. H., B. Leohard, et al. (1993). "Tauridine: in vitro activity against multiple-antibiotic-resistant, nosocomially significant clinical isolates of *Staphylococcus aureus*, *Enterococcus faecium*, and diverse *Enterobacteriaceae*." *Chemotherapy* 39(5): 322-30.
- Weber, M., F. Weyer, et al. (2009). "Spectrum of indications and perioperative management in i.v. port-a-cath explantation-alternative administration of taurolin in case of i.v. port-a-cath infection." *Zentralbl Chir* 134(4): 350-6.
- Wejmer W. C. et al. (2002). "Randomized, Clinical Trial Comparison of Trisodium Citrate 30% and Heparin as Catheter-Locking Solution in Hemodialysis Patients." *Nephrol Dial Transplant* 2002; 17: 2189.
- Zhao, Y., Z. Li, et al. (2014). "Citrate Versus Heparin Lock for Hemodialysis catheters: A Systematic Review and Meta-analysis of Randomized Controlled Trials." *Am J Kidney Dis* 63(3): 479-90.

Zalety

Geistlich
TauroSept®



	Brak efektów ubocznych		Efekt antybanteryjny		Skuteczność przeciw grzybom	
	Brak niekorzystnych efektów przestrzyknięcia, zatkania, wycieku	Szerokie spektrum	Szczególnie skuteczny przeciwko kandydozie	Brak efektów ubocznych	Efekt antybanteryjny	Skuteczność przeciw grzybom
2% Taurolidyna	✓	✓	✓	5, 9, 17, 18, 27, 28	✓	11, 16
1,35% Tauroloidyne + 4% Cytrynianu	✗	✓	✓	4, 8, 24	✓	2
Heparyna	✗	✗	✗	25	✗	1
Roztwór soli fizjologicznej	✓	✗	✗	10	✗	✗
30% lub 46% cytrynian	✗	✓	±	20, 21, 3, 30, 31	±	3
4% Cytrynian	✗	✗	✗	4, 19, 20, 31	✗	3
Etanol	✗	✓	✗	14, 15	✗	18
Antybiotyki	✗	✓	✗	12	✓	13
Działanie na biofilm	Antyadhezyjne i zniszczające bakterie w biofilmie	Zapobieganie rozwojowi biofilmu	Brak odporności	Osmolarność	Działanie przeciw zakrzepowe	
✓	6, 11, 29	✓	5, 6, 11	✓	16, 17	9
✓	26	✓	4, 8, 24	✗	✓	22
✗	25	✗	25	✗	✓	2
✗		✗		✓	✓	✗
✓	30	✓	3, 10	✗	✓	19, 23
✗	12, 20	✗	20, 31	✗	✓	20, 2
✓	15	✓	✓	✗	✓	24
✓		±	±	±	✗	✗